Gallery
Menu
© Copyright DxPx 2021. All Rights Reserved. Developed By: Menthamedia AG
Aescuvest is driven by a team of specialists in medicine and technology, finance and law, marketing and sales as well as accompanying faculties. #InvestInHealth with us and connect money with innovation.
AirMed International is part of the Global Medical Response family of companies, and is committed to providing care to the world at a moment’s notice. We are one of the leading air medical transport companies in the world, with over 25,000 total missions and counting. AirMed offers unparalleled medical care and bedside-to-bedside transportation on a worldwide basis and boasts some of the most experienced air medical crews in the industry. Chosen as a preferred operator for many of the top hospitals around the globe, as well as a contracted carrier for the U.S. Department of Defense, AirMed operates its own fleet of fully customized and permanently configured jets.
We believe in the unique chance china offers. We manage and build funds for public and non- public equity investments into technology companies between China and Europe. Furthermore, we offer strategy advisory services to selected client.
Providing up to $1M to Deep Tech startups in Europe, we give groundbreaking innovations the boost they need to succeed. On top of capital, we support early-stage teams with over a decade of first-hand experience in business and product development, and a global network that reaches from Silicon Valley to China’s Greater Bay area. Our fund was co-created with the PFR Starter FIZ program from PFR Ventures.
We are not interested in following the crowd. We are contrarian, bold, and imaginative risk takers. We follow the science to found companies based on revolutionary technologies that can impact people’s lives.
Angine is an international business development solution provider company dedicated in the pharma, biotech and medical device fields for the global business partnership building.
Angels Santé is a networking site for investors and companies in the health sector. The EIT Health Investor Network aims to facilitate early stage fundraising of qualified companies by connecting them to a pool of selected equity investors such as Corporate VCs, early stage VC’s, Family offices, Angel Networks or Super Angels across Europe.
Founded in 2016, aMoon Fund is a venture capital firm based in Ra’anana, Israel. The firm seeks to invest in early and late-stage companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. The firm seeks to invest in the HealthTech and life sciences sectors.
Am Hafen Capital is a venture capital firm based in Hamburg, Germany. The firm seeks to invest in the business products and information technology sectors.
Asclepius was the Greek god of medicine and healing. aescuvest derives from his Latin name, Aesculapius, and from ‘investment’. aecusvest has created an interactive network to bring together everyone with an interest in pushing forward the health sector.
Our mission is to help our clients enter the China market so that Chinese people may have access to the top medications and treatment methods in the world.
Aescuvest is driven by a team of specialists in medicine and technology, finance and law, marketing and sales as well as accompanying faculties. #InvestInHealth with us and connect money with innovation.
Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. We invest in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health. Our strategic relationship with Illumina provides us access to the expertise and vision of the world’s leading genomics solutions provider. Our team members have decades of entrepreneurial experience in genomics and a passion for improving human health.
ZFHN – Zukunftsfonds Heilbronn has been one of the largest venture capital funds in Germany since its founding in 2005. Above all, he supports young, innovative technology companies based in the Heilbronn area or willing to settle there in the short to medium term. The ZFHN is privately financed and has equity in the hundreds of millions in euros. ZFHN wants to help build the next generation of medium-sized market leaders in the Heilbronn area. He is building up high-tech companies by promoting them with capital and know-how. The goal is to develop Heilbronn into a successful technology location. As a privately financed fund, the ZFHN is independent of investment funds, banks, savings banks and state bodies. The ZFHN management acts as a long-term entrepreneurial partner with a long-term investment period. ZFHN supports his young investment companies with controlling, strategy consulting and network contacts.
Wellington Partners is one of the most successful pan-European venture capital firms. With funds totalling over € 800 million, we have invested throughout Europe in companies that have the potential to become real market leaders for more than 15 years. We are committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically lead financing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, our own commitment can go as high as € 15 million. Providing funding is only one part of our business. After funding, the entrepreneurs we back have access to the advice and guidance of our complete team and our entire global network. Our investment professionals operate out of four offices, located in London, Munich, Zurich and Palo Alto. The pan-European and transatlantic makeup of our organisation enables us to support our portfolio in expanding globally. To date, Wellington Partners has invested in more than 100 companies throughout Europe. We have been a part of great successes as well as dismal failures. In our view, success has always been the result of a great idea executed by a great team with strong leadership and commitment; plus an enormous amount of hard work and an ounce of luck, the good fortune to be in the right place at right time.
Warson Capital Partners was founded as Frontenac Financial Group, Inc. in 1994 to serve the capital needs of emerging growth companies with a focus on the Midwest within a growing national presence. Throughout our history, Frontenac — now Warson Capital Partners — has represented numerous clients in first- and second-round equity financings, senior and mezzanine debt financings, start-up situations, turn-around challenges, sell-side and buy-side mergers and acquisitions, recapitalizations, and bridge financings. Recognizing our commitment to our clients and the successful transactions we have achieved for them, many of our clients have looked to us for multiple engagements to support their growth, spanning from first-round financings to lucrative exits from their business investments. Many of those long-time clients are now committed investors within our private equity fund.
As a high-tech company, TRUMPF provides manufacturing solutions in the fields of machine tools, laser technology, electronics, and Industry 4.0.
Touchdown partners with leading corporations to manage their venture capital programs. Our team has founded or managed more corporate venture programs than anyone else—we provide professional expertise at scale to bridge the divide between big and small companies.
Tosoh Corporation is the parent company of a Japanese chemical and specialty products and materials group that comprises over 100 companies worldwide and a multiethnic workforce of more than 12,000 people. The parent company was established in 1935 and is listed on the First Section of the Tokyo Stock Exchange. In the more than 80 years that we have been in business, we have built balanced product lines of commodity chemicals for industry and of specialty products and materials for high technology and niche markets.
For more than 45 years, we have been involved in and for the domestic SME sector. With an invested volume of 300 million euros, we are one of the leading SME-oriented investment companies and contribute to the successful development of our portfolio companies as a reliable, effective partner with equity and mezzanine capital.
We have more than 20 years of genomics experience helping our customers achieve their research goals by delivering rapid, high quality results using a broad array of cost-effective, cutting-edge technologies, including our own innovative DNBseq™ sequencing technology.
Taikon Advisor is a company founded 2010 by Seppo Mäkinen and from 2017 part of Noribe Group. Our main activities are management consultancy mainly in companies operating on medical, diagnostics, healthcare technologies and cleantech sector.
Our main focus is on helping companies in strategic planning, M&A activities, fund raising, networking with partners and management search. Our main focus is in the Nordic countries and Portugal but because of long international history we are also active in Europe. Through our extensive international networks we can assist our customers also outside Europe.
Since 2013 we’ve backed over 120 European SMEs from a wide range of geographies across Europe. The Claret team have been active in the technology financing markets for over 20 years.
CS Ventures is the corporate venture fund initiative of Canterbury Scientific Ltd., a leading OEM developer and supplier of high quality in vitro diagnostic controls and calibrators for diabetic and haemoglobinopathy applications worldwide. CS Ventures was established in 2019 to invest in promising IVD opportunities that align with Canterbury Scientific’s existing capabilities and to diversify into applications beyond diabetes mellitus.
Crowberry Capital invests at seed and early stage in outstanding teams building global businesses around true technology advantages. We work with our teams to build fast paced, international companies from the Nordics. We have a strong follow through philosophy. We back the best from seed to exit.
Crowberry Capital invests at seed and early stage in outstanding teams building global businesses around true technology advantages. We work with our teams to build fast paced, international companies from the Nordics. We have a strong follow through philosophy. We back the best from seed to exit.
Crowberry Capital invests at seed and early stage in outstanding teams building global businesses around true technology advantages. We work with our teams to build fast paced, international companies from the Nordics. We have a strong follow through philosophy. We back the best from seed to exit.
Due to our independence we are flexible, pragmatic, and able to act swiftly. All our decisions focus on increasing the value of our portfolio companies – always taking a long-term perspective bereft of any short-term opportunism.
Due to our independence we are flexible, pragmatic, and able to act swiftly. All our decisions focus on increasing the value of our portfolio companies – always taking a long-term perspective bereft of any short-term opportunism.
Convergence Partners was formed in 2018 by experienced venture capital and operational experts with a vision to establish a venture capital firm that actively supports the internationalisation and market access of European technology innovators to large Asian markets, with a particular focus on China and India.
Convergence Partners was formed in 2018 by experienced venture capital and operational experts with a vision to establish a venture capital firm that actively supports the internationalisation and market access of European technology innovators to large Asian markets, with a particular focus on China and India. Whereas our current investment focus is on EU HealthTech startups, Convergence is able to open its established EU-Asia cross-border acceleration platform to any Deeptech company that is keen to realise the enormous Asia market potential.
The Chemical Angel Network measures its success by the quality of deal flow, amount of dollars invested, number of companies funded and most importantly ROI for members.
We have more than 20 years of genomics experience helping our customers achieve their research goals by delivering rapid, high quality results using a broad array of cost-effective, cutting-edge technologies, including our own innovative DNBseq™ sequencing technology.
Capricorn Partners is an independent manager of private and quoted equity funds that invest in minority shareholding positions of innovative companies with technology as competitive advantage.
Button Capital Limited is a global private equity real estate investment company founded in 2013. Our mission is to source, acquire, optimize and manage-to-exit value add and opportunistic real estate transactions in an ever-changing environment. We do so with our team of professionals whose broad experience in the real estate sector spans the globe, bringing a wealth of expertise in underwriting, structuring and optimizing diverse types of real estate investments. Button’s investors include family offices, endowments and professional investors across Asia and the United States. Button’s main investment classes include value-add and core plus multifamily, preferred equity and mezzanine debt in the United States, as well as master lease projects in China.
BAND stands for the guiding principle of the “two-winged” business angel, who participates in young, innovative start-ups with both capital and know-how. Business angels are often at the beginning of the financing chain, where the bottleneck is greatest. In addition, business angels increasingly play a not insignificant role in follow-on financing rounds. For these reasons, they are of great economic importance.
btov is a European venture capital firm, managing about EUR 510m in institutional funds, partner funds and direct investments of private investors. btov teams in St.Gallen, Berlin, Munich and Luxemburg jointly with seasoned entrepreneurs back Start-ups with teams willing to make the difference.
btov is among the largest and oldest venture capital firms in Europe. Founded in 2000, originally as online matching platform named “BrainsToVentures”, btov has pioneered venture capital investment solutions for private, corporate and institutional investors. We share their risk since we invest significantly in our funds and have “skin in the game”.
btov is a European venture capital firm, managing about EUR 510m in institutional funds, partner funds and direct investments of private investors. btov teams in St.Gallen, Berlin, Munich and Luxemburg jointly with seasoned entrepreneurs back Start-ups with teams willing to make the difference.
btov is among the largest and oldest venture capital firms in Europe. Founded in 2000, originally as online matching platform named “BrainsToVentures”, btov has pioneered venture capital investment solutions for private, corporate and institutional investors. We share their risk since we invest significantly in our funds and have “skin in the game”.
Founded in 1993, Brandenburg Kapital is a venture capital investment firm based in Potsdam, Germany. The firm seeks to invest in startups and small and medium-sized enterprises operating in the information, communication technology, life science, nanotechnology, industrial and technology sectors in Brandenburg.
Founded in 1993, Brandenburg Kapital is a venture capital investment firm based in Potsdam, Germany. The firm seeks to invest in startups and small and medium-sized enterprises operating in the information, communication technology, life science, nanotechnology, industrial and technology sectors in Brandenburg.
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation. Since 2010, we invest in pioneering science that offers the potential to provide a significant benefit for our patients. Since innovation is not restricted by geography, we invest worldwide.
Techniker (TK) is a nationwide statutory health insurance company with 9.8 million insured persons. Techniker Krankenkasse is repeatedly awarded for its benefits and service.
Sigma Ventures, Inc. of the United States operates as a private equity firm. The Company invests a wide range of sectors, including cable television, food and beverage, pharmaceuticals, energy, consumer goods, retail, agriculture, chemicals, metallurgy, shipyards, and commodities. Sigma Ventures serves customers in the United States.
We have never strayed from the clarity of our intention or the inspiration of that swift-flowing river. We adapt quickly to the changing flow of business and the evolution of technology, but our guiding principles—continuous improvement and customer satisfaction—remain rock solid.
Capricorn Partners is an independent European manager of venture capital and equity funds, investing in innovative companies with technology as competitive advantage. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience. Capricorn Partners is investing out of the private venture capital funds Capricorn Digital Growth Fund, Capricorn Sustainable Chemistry Fund, Capricorn ICT Arkiv Fund, Capricorn Health-tech Fund and, recently added, Capricorn Fusion China Fund. Capricorn Partners is also the management company of Quest for Growth, quoted on NYSE Euronext Brussels, and the investment manager of Quest Cleantech Fund and Quest+, sub-funds of Quest Management SICAV.
ENGELHARDT KAUPP KIEFER & Co. invest in challenges. That is why we do not refer to ourselves as industry specialists, but rather as situation specialists. With a holistic understanding of what success actually has to mean today. We invest in companies with a turnover between EUR 1.0 million and EUR 10.0 million and bring an equity commitment of up to EUR 2.0 million.
Egis Capital Partners is a private equity firm uniquely focused on the Security and Protection industry, a growing market for products and services that protect people, assets, and information. With more than 75 years of collective operating and investing experience and industry executives as investors, Egis is a provider of equity capital to businesses providing critical physical and technology-driven security solutions. Egis Capital Partners makes control-oriented buyout and growth investments in technology-driven businesses in the Security and Protection industry. Egis targets companies in North America with enterprise values ranging between $30 million and $200 million that require a total equity investment between $10 million and $80 million.
Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets. Earlybird manages different funds with focuses on digital technologies in Eastern and Western Europe as well as health technologies. With over EUR 1 billion under management, seven IPOs and 22 trade sales, Earlybird is one of the most successful venture capital firms in Europe.
DigitalDx Ventures is a majority woman-owned impact fund comprised of a team of successful Silicon Valley digital health investors, medical and legal professionals leveraging AI and big data technologies to diagnose major global health issues such as breast and other cancers, cardiovascular and kidney health, Alzheimer’s disease, and mental health) with a particular focus on: 1. Enabling early, more accurate detection; 2. Minimizing invasiveness; 3. Expanding access to treatment (through lowered costs).
As one of the world’s leading exchange organizations Deutsche Börse Group provides investors, financial institutions and companies access to global capital markets. Our business covers the entire process chain from securities and derivatives trading, clearing, settlement and custody, through to market data and the development and operation of electronic trading systems. Our reliable systems and our integrity as a neutral provider form the basis of our business philosophy. We operate to the most exacting standards to create products and services to meet the needs of international financial markets. As a listed company we work to create value for our customers and our shareholders.
We’re the Life Sciences newcomer you already know. Cytiva is bringing our long-standing expertise to the forefront of science, to fuel research, discovery, and development with technologies, instruments, and software. We drive customer-centered innovation in 11 facilities across Asia, Europe and America from idea to commercial development stages.
CS Ventures is the corporate venture fund initiative of Canterbury Scientific Ltd., a leading OEM developer and supplier of high quality in vitro diagnostic controls and calibrators for diabetic and haemoglobinopathy applications worldwide. CS Ventures was established in 2019 to invest in promising IVD opportunities that align with Canterbury Scientific’s existing capabilities and to diversify into applications beyond diabetes mellitus.
Robert Bosch GmbH (/bɒʃ/; German:), or Bosch, is a German multinational engineering and technology company headquartered in Gerlingen, near Stuttgart, Germany.
Esplanade Ventures is an early-stage digital health venture fund. Initially formed in 2019 by the founders of Medisys Health Group and Persistence Capital Partners, Canada’s largest Healthcare Private Equity firm. Our team creates value using our deep healthcare knowledge, extensive network, active strategic direction, and key partnerships through distribution channels.
We are led by owners and operators of healthcare businesses within Canada and globally with over 85 years of combined experience. Our team is working to establish a leading, interconnected digital health ecosystem that successfully scales portfolio companies to drive digital health innovation globally. We have offices in Montreal and Toronto.
BORN2GROW invests in start-ups that offer truly innovative ideas, and a management team with the skills and grit to achieve sustainable growth. We partner with companies at an early stage, but our private funding allows us to form long-term relationships that may involve our parent company, Zukunftsfonds Heilbronn (ZFHN).
ADVANCING THE GROWTH OF MEDTECH: We are partner with the innovators who are changing the practice of medicine. BioVentures MedTech Funds invests in companies that are developing today’s leading-edge biomedical technologies. Together, we create dynamic solutions that improve health outcomes and reduce the cost of care.
BioMap is an AI driven research and development platform focusing on precision medicine that is co-founded by Baidu Corporate’s founder/CED Robin Li and former Baidu Ventures CEO Wei Liu.
Avego was founded in 2015 by former healthcare entrepreneurs with a passion for building high growth, market-leading companies. Our operational focus is our defining character. We are entrepreneurs and investors dedicated to partnering with highly motivated healthcare executives who have a passion for building category-defining businesses.
Avego was founded in 2015 by former healthcare entrepreneurs with a passion for building high growth, market-leading companies. Our operational focus is our defining character. We are entrepreneurs and investors dedicated to partnering with highly motivated healthcare executives who have a passion for building category-defining businesses.
Over 30 years, ARCH has backed disruptive science with as little as $50K and as much as $150M, per company.
We are not interested in following the crowd. We are contrarian, bold, and imaginative risk takers. We follow the science to found companies based on revolutionary technologies that can impact people’s lives.
We take a long-term view when building companies. That’s why we are flexible in our approach and will invest $50K to $150M in a single deal. Our extended network of partners helps us build companies through the formation stages and grow to their full potential.
aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with over $1.1 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives. We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality. Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through seed A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.
Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today
EQT is a purpose-driven global investment organization with close to three decades of consistent investment performance across multiple geographies, sectors, and strategies.
Young startups will change the world. To support them with capital and know-how at an early stage, we’re building Germany’s first student-run VC.
At SHS Capital we are committed to Building European Healthcare Champions, by helping to accelerate our portfolio companies’ growth. We do that by following high ethical and sustainable standards. If you are looking for the right partner to bring your Healthcare company to the next level, reach out!
Mighty Capital is an early-growth Silicon Valley venture capital (VC) firm. We deliver exceptional returns by investing in great products that are also great businesses, like Airbnb, MissionBio and Amplitude. Founders and other VC firms invite us to invest because we help our portfolio companies sell faster, hire top talent, and generate liquidity, by giving them exclusive access to the original and most influential product acceleration platform, Products That Count. Amplitude calls us the “best value for the dollar invested.” Learn more at Mighty.Capital.
Seroba is a European life sciences venture capital firm focused on investing in winning innovations in biotech and medtech. The team has deep investment and industry experience enabling Seroba to help entrepreneurs realise their ambitions whilst creating value for investors. The firm has three funds under management and has built a portfolio of investee companies across multiple indications. Seroba partners with entrepreneurs to create and build businesses around extraordinary science.
SCOR, one of the world’s largest reinsurers, provides its clients with a diversified and innovative range of solutions to control and manage risk. Using its experience and expertise, “The Art & Science of Risk”, SCOR provides cutting-edge financial solutions, analytics tools and services in all areas related to risk – in Life & Health as well as in P&C. The reinsurance industry is about combining technical expertise and experience with the developments of science. However many tools we use to conduct our activities (models, databases, pricing tools, reserving tools, and so on), we also need expert judgments and human experience to correctly underwrite. This is what we call the art of underwriting. Reinsurance is a knowledge industry. Expertise is an accumulation variable.
Scientific Health Development (“SHD”) is a boutique investment company located in Dallas, TX. SHD invests in early-stage, innovative healthcare-related technologies and products.
Panakes is a venture capital firm with the ultimate goal of providing a better life to people all around the world. We back promising teams by providing both financial and business support to build the next generation of game-changing technologies companies in the field of Life Sciences. We invest in ambitious early stage start-ups and SMEs with innovative products globally, mainly across Europe and Israel. We bring strong entrepreneurial and financial expertise to portfolio companies well beyond just capital, relying on a wide network of clinicians and industry experts. We have established relationships with selected industrial partners to assist our founders in accelerating their development. We invest in people, believing that a strong and dedicated team is one of the most important factors in the success of our investments. We aim to work together with entrepreneurs to develop successful businesses as an active and well-connected investor. We invest for people, supporting the growth of companies and people that will reshape the medical world, answering real medical needs, saving lives and providing a better quality of life for patients and care-givers. An overall positive impact that will produce intrinsic value for both investors and society. Panakes derives from Panacea (Greek Πανάκεια, Panakeia), who was the goddess of Universal remedy, said to have a potion with which she healed the sick.
Outsized Ventures is an early stage VC fund based in London that partners with founders pushing the boundaries of science and technology to solve the world’s greatest challenges.
MVM Partners has been a life science investment fund for more than 20 years and invests broadly across the healthcare sector, including in specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, healthcare services, and digital health. MVM has a global perspective on healthcare and maintains offices in Boston and London. Current MVM portfolio companies are headquartered in the US and Europe, and many have extensive operations in the Middle East and Asia.
MVM Partners has been a life science investment fund for more than 20 years and invests broadly across the healthcare sector, including in specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, healthcare services, and digital health. MVM has a global perspective on healthcare and maintains offices in Boston and London. Current MVM portfolio companies are headquartered in the US and Europe, and many have extensive operations in the Middle East and Asia.
MVM Partners has been a life science investment fund for more than 20 years and invests broadly across the healthcare sector, including in specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, healthcare services, and digital health. MVM has a global perspective on healthcare and maintains offices in Boston and London. Current MVM portfolio companies are headquartered in the US and Europe, and many have extensive operations in the Middle East and Asia.
MGI, a member of BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI produces sequencing instruments, reagents, equipment and related products to support life science research, agriculture, medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include sequencing, medical imaging and laboratory automation. Providing real-time, comprehensive, life-long solutions, its vision is to lead life science innovation.
Graham Partners is a middle-market private equity firm investing in technology-driven companies that are spurring innovation in advanced manufacturing.
Founded in 2015, LYFE Capital is a dedicated healthcare fund with $1.27 billion in assets under management. We are actively seeking healthcare companies with exceptional management teams and expansive vision geared towards global markets.
At LYFE, we share the passion of our entrepreneurs in their objectives of striving for a better world; one step at a time. Not only do we invest in healthcare but we also bring significant deep seated China knowledge and international business experience to accelerate our partners in their growth, expanding a strong stable company more readily to take on the challenges in the China market.
Founded in 2015, LYFE Capital is a dedicated healthcare fund with $1.27 billion in assets under management. We are actively seeking healthcare companies with exceptional management teams and expansive vision geared towards global markets.
Imec.xpand is a revolutionary way of investing in early stage innovation on the crossroads of technology transfer, corporate venturing and traditional venture capital. The fund will heavily leverage the extensive technology, knowledge, vision and expertise of imec and of its strategic investors, targeting nanoelectronics-based innovation projects in smart applications for a sustainable society such as smart health, smart mobility, smart cities, smart industries, smart energy.
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3 billion into the HTGF portfolio via more than 1,700 follow-on financing rounds. HTGF has also successfully sold interests in more than 130 companies.
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3 billion into the HTGF portfolio via more than 1,700 follow-on financing rounds. HTGF has also successfully sold interests in more than 130 companies.
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3 billion into the HTGF portfolio via more than 1,700 follow-on financing rounds. HTGF has also successfully sold interests in more than 130 companies.
Ding Shi Technology Limited is a cross-border integrated enterprise positioned in technology innovation and technology incubation. Based in the Chinese market, the company focuses on cutting-edge global innovation and technology, and is committed to discovering innovative global technologies/products, combining Chinese market resources, business models and industrial capabilities to build and incubate world-leading technology companies made in China.
Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020.
Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence.
ZFHN – Zukunftsfonds Heilbronn has been one of the largest venture capital funds in Germany since its founding in 2005. Above all, he supports young, innovative technology companies based in the Heilbronn area or willing to settle there in the short to medium term. The ZFHN is privately financed and has equity in the hundreds of millions in euros.
At Plug and Play, our core objective is to catalyze technological advancement. Over the past 15 years, we have built the largest innovation platform on the planet, bringing together startups, investors, and blue chip corporations. We are now active in 30+ locations globally, including U.S., China, France, Germany, The Netherlands, Singapore, Indonesia, and Mexico.
Republic curates private investing opportunities with high-growth potential across startups, gaming, real estate, and crypto.
Billions of tax refunds remain unclaimed because the tax refund submission process in many European countries is too cumbersome and intransparent. Through an intuitive and automated mobile-first process, Taxfix makes tax refunds transparent and accessible.
Through further training, specialist contributions and international delegation travels, Pinzhi is involved in the national reform of the Chinese health system and combines high-quality medical education from East and West. Phinzi’s mission is to improve the technical and management skills of Chinese medical professionals and to train innovative managers with international insights that contribute to the well-being of the population. In the future, Pinzhi will continue to spread its innovative strength, experience and expertise into the world in order to enable stronger cooperation with the Chinese health care system and to establish itself as the brand for advanced training in the Chinese health care.
Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.
Portugal Ventures, a venture capital firm that is part of the Banco Português de Fomento group, currently manages 173 million euros and has more than 130 portfolio companies. It invests in startups in the pre-seed, seed and series A stages that offer innovative solutions for the international market in the digital, engineering & industry, life sciences, and tourism sectors.
ZFHN – Zukunftsfonds Heilbronn has been one of the largest venture capital funds in Germany since its founding in 2005. Above all, he supports young, innovative technology companies based in the Heilbronn area or willing to settle there in the short to medium term. The ZFHN is privately financed and has equity in the hundreds of millions in euros.
We want to build a smart future. To achieve that, we’re building a unique ecosystem that connects change-makers and leading organizations.
The combination of complementary skill sets and interdisciplinary technical expertise, in conjunction with a comprehensive national and international network in the healthcare sector, enables PVP to guide all of a company’s key stages of development, from start-up, and financing rounds through growth stages and strategic exits. Since the year 2000, PVP team members have been working in various constellations on various deals and exits.
Goddess of health and prosperity, Salus is the personification of well-being in health, and in wealth, for both the individual and the society.
PATHENA is a Venture Capital firm boosting the success of European Information Technology and Digital Health companies. The team is composed by an experienced group, working together for more than 15 years. With strong international track-record in Entrepreneurship and Venture Capital in Technology and Digital Health, the in-house expertise is complemented by world-class industry experts.
Our Medical Business works with health care professionals to combine our innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing with their skills to deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance quality of life for patients. For more information, visit http://medical.olympusamerica.com.
We are an international venture capital investor with offices in Zug and Munich, are owner-managed and invest our own wealth. We seek to make a positive contribution to society through sustainable, meaningful investments.
The Mission Statement encapsulates NRW.BANK’s mission in concise and easily understandable statements, ensuring that the institution speaks with a single voice and projects a clear message to the public. The Mission Statement of NRW.BANK was developed and discussed in two workshops attended by the Managing Board, representatives of the business units and members of the Executive Circle.
NRW BANK is a banking institution founded in 2002 and is based in Düsseldorf, Germany. The bank provides banking products and services in Germany.
NRW BANK is a banking institution founded in 2002 and is based in Düsseldorf, Germany. The bank provides banking products and services in Germany.
We are committed to preserving our planet’s natural resources and ensuring the health and safety of our employees, families and communities. We demonstrate our dedication by practicing sustainability, advocating for volunteerism and promoting philanthropy to make the world a better place.
We believe that everyone has a right to experience and to enjoy good health. Therefore, we are paving the way for founders & startups to make their digital health solutions desirable, impactful and available to people. Rooted in Roche, we turn ideas into healthcare businesses and launch & scale innovations into the healthcare system.
SFW Capital Partners is a specialized private equity firm that invests in leading Information, Software, Industrial and Healthcare Technology companies, where our 25+ years of investing in and experience with the relevant business models, technologies, competitive dynamics and service requirements gives us confidence in our ability to support management teams in growing their companies and building value.
Obtain investment return for Cornell University and its faculty and staff inventors, and create jobs and advance economic impact for New York State
The tyrolean business angel network is a network of private investors, who are looking to support the startup ecosystem in the Alpine region. The tba network is, therefore, an important interface between startups and leading international companies
As a founder of an innovative technology start-up, you can benefit from our well-established fund structure. No matter whether you need an investment or knowledge for your further growth, we are here to support you and your enterprise. We are your partner on your journey, not only your investor. Therefore, we offer a broad network within the German Mittelstand and, with our team members being skilled in various industries, we will provide you with exactly the knowledge you need.
https://www.zf-hn.de
Our founders see further and push farther. They are courageous visionaries who are redefining tomorrow by pushing innovation and creating impact. We are partners determined to provide exceptional support on their journey to success.
In the last decade, we have completed transactions with a total value in excess of £8.0 billion.
Our business is 100% owned by the partners who combine more than 250 years of relevant experience.
We bring a truly international perspective, acting for corporate and institutional clients across
the UK, Europe, USA, Asia and Australia.
Since the 1990s we have been delighted to support the global ambitions of Europe’s best entrepreneurs and to help them become global leaders in their businesses
Vigintillion Capital focuses on private equity investment in life sciences and healthcare. We mainly invest in promising growth and maturity stage companies in China and abroad.
We are founded by industry veterans and supported by several well respected financial and industrial conglomerates. While creating value for investors, we adhere to the principle that financial investment should be performed with industrial aspiration in mind. In all of our proposed or invested projects, we have proposed or transmitted tailor-made strategic values to target companies to support their long-term development.
We are investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe. Our portfolio companies address unmet medical & market needs and operate on the basis of strong intellectual property protection.
We invest in the most promising European startups and systematically accelerate their growth. We focus on digital, tangible and health technologies and invest from the Seed Stage onward.
Two decades of early-stage investing in Europe’s most ambitious entrepreneurs.
Tosoh USA, Inc. was initially established as Tosoh Corporation’s first US representative office in NY in 1964 and has grown to become the corporation’s main sales, marketing, and business development center in North America. Currently, based in Grove City, Ohio, Tosoh USA markets and sells a variety of chemical products produced by Tosoh Corporation and its affiliates that go into a myriad of industries and markets. Silica glass (a.k.a. quartz), organic chemicals, and specialty polymers are just some of the essential Tosoh USA provides to customers who produce everyday things.
Fosun Pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. Through in-house R&D, co-development, in-licensing and incubation, Fosun Pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy, focusing on major therapeutic areas, including oncology, immunology, “4 hypers” (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system.
1315 Capital provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty therapeutics companies, the latter including businesses focused on cost containment and digital health. We believe that these investment areas are attractive largely due to numerous […]
Entrepreneurial passion is contagious. Engaged founding teams, who stand 100% behind the common idea, are our target group. As far as the idea is concerned, once we are open to everything, it should answer the question: “What solution do you have for what problem? With the TechVision Fonds and associated co-investors, we can finance startups with our investment, from the product idea to the foundation to the prototype.
Our main focus is on helping companies in strategic planning, M&A activities, fund raising, networking with partners and management search. Our main focus is in the Nordic countries but because of long international history we are also active in Europe. Through our extensive international networks we can assist our customers also outside Europe. Taikon Advisor Oy is a partner in the international Ventac Partners management consultancy network and forms up the unit Ventac Partners, Finland.
We develop, produce and sell devices and consumables for medicine and science. We are known as one of the leading providers in this sector worldwide.
Summa Equity invests in companies that have leading solutions to global challenges and that create positive Environmental, Social, and Governance (ESG) outcomes for society. We co-create win-win for our investors, our companies, and society through aligning our vision and outcomes to the Sustainable Development Goals, ensuring a net-positive impact against ESG challenges, and the potential for long-term, sustainable outperformance.
Stetson Family Office has formed two foundations – Essentials in Education (EIE) and Healthcare Impact Foundation (HCIF). EIE is building global platforms in education addressing the increasing gap between what young people need to know and what they are taught. HCIF’s goal is to reduce healthcare costs globally and rebuild the private equity healthcare ecosystem.
Over the years STAR has built up an excellent track record in value generation. The three most senior members of the team have worked together since inception and have been significantly involved in almost all STAR investments.
We build European healthcare champions. To this end, we invest in fast-growing companies in the healthcare sector and help in particular to open up new markets, round off the product portfolio, in succession situations and in financing company acquisitions.
Louis Walcer
M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck KGaA, Darmstadt, Germany‘s core business areas.
We have never strayed from the clarity of our intention or the inspiration of that swift-flowing river. We adapt quickly to the changing flow of business and the evolution of technology, but our guiding principles—continuous improvement and customer satisfaction—remain rock solid.
Fannin Innovation Studio is an early-stage life sciences development group focused on commercializing innovation developed in the Texas Medical Center institutions.
HTGF is THE seed investor for innovative technologies and business models. We are successful in supporting the best founders whose ideas can revolutionize entire industries and improve people’s lives. From the foundation of a start-up to its exit.
An early stage venture capital firm we invest in companies with technology for precision medicine diagnosis. The technologies in focus have the characteristics of very high specificity and the capability to dramatically improve the choice of optimum therapy and reduce cost.
Gimv is a European investment company, listed on Euronext Brussels. With 40 years’ experience in private equity, Gimv currently has EUR 2 billion of assets under management. The portfolio contains around 50 portfolio companies, with a combined turnover of EUR 2.5 billion and 14,000 employees.
Gilde Healthcare is a specialized European healthcare investor managing EUR 1.4 billion (USD 1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.
German Accelerator empowers German startups to scale globally. We take high potential companies on a fast-paced learning journey in the world’s leading innovation hubs in the U.S. and Asia.
Genscript Biotech Corporation is a global biotech company. The Company’s mission is to “Make the Human and Nature Healthier through Biotechnology”. Genscript Biotech Corporation is a leading life sciences research and application service and product provider that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions.
As a “first money in”-investor, we help your startup to gain its first momentum by backing you with a first investment as well as world-class mentoring, a strong community, and the required know-how. We are engineers at heart, investors by choice – we are going to ask for your business model, but also geek out with you over your technical approach.
We invest in B2B startups with novel technologies and innovative business models with a strategic link to ams and OSRAM. We seek to accelerate your growth by leveraging their leading position in the high-tech lighting, photonic as well as sensor industry. Yet, our investment scope goes well beyond pure illumination. Have a look at our focus areas and funding criteria.
Elevation Partners was a trail blazing $1.9 billion private equity investment fund focused on the intersection between technology and media. Elevation made a total of eight investments, beginning in 2005 with a videogame developer, BioWare / Pandemic Studios (acquired by Electronic Arts). The fund later made large, private investments in Facebook and Yelp several years before they went public. Other investments included Forbes Media (acquired by Integrated Whale Media), Palm (acquired by Hewlett-Packard), and MarketShare (acquired by Neustar). The fund’s activities were completed successfully in 2015 with the sale of its last portfolio company.
HTGF is THE seed investor for innovative technologies and business models. We are successful in supporting the best founders whose ideas can revolutionize entire industries and improve people’s lives. From the foundation of a start-up to its exit.
Our network connects world-class organisations across Europe from the three worlds of business, research and education. We call this meeting point the ‘knowledge triangle’ because it’s where life-changing ideas happen.
Earlybird Venture Capital has grown to three autonomous, dedicated and specialized teams, focusing on different geographies and sectors. The Digital West Fund focuses primarily on early stage digital technology opportunities in GSA, Nordics, UK, Benelux, France and Southern Europe, while the Digital East Fund is focused on early stage ICT investment opportunities in Eastern Europe and Turkey, being the leading tech VC in this region. The Health Fund focuses on early and later stage opportunities in digital health, medical devices, diagnostics, enabling technologies and biopharma across Europe.
Earlybird Venture Capital has grown to three autonomous, dedicated and specialized teams, focusing on different geographies and sectors. The Digital West Fund focuses primarily on early stage digital technology opportunities in GSA, Nordics, UK, Benelux, France and Southern Europe, while the Digital East Fund is focused on early stage ICT investment opportunities in Eastern Europe and Turkey, being the leading tech VC in this region. The Health Fund focuses on early and later stage opportunities in digital health, medical devices, diagnostics, enabling technologies and biopharma across Europe.
Advances in novel therapeutics including complex biologics, vaccines, cell & gene therapies and regenerative medicine are creating the demand for novel, purpose-built tools and technologies. A.I. and machine learning, microfluidics, automation and disruptive service models are evolving faster than ever before. This convergence of technology is giving rise to new opportunities across life sciences.
We are a concept and participation agency in healthcare, focusing on our Triple P: Prevention, Care and Patient Orientation.
Die Deutsche Börse AG ist eine deutsche Aktiengesellschaft mit Sitz in Frankfurt am Main. Kerngeschäft ist die Entwicklung und der Betrieb von Handelsplattformen, Teilnehmernetzwerken und Abwicklungssystemen für Börsen.
From account services to global investment expertise – we provide a wide range of solutions for your financial needs. For more information, we encourage you to consult our friendly staff.
From account services to global investment expertise – we provide a wide range of solutions for your financial needs. For more information, we encourage you to consult our friendly staff.
HTGF is THE seed investor for innovative technologies and business models. We are successful in supporting the best founders whose ideas can revolutionize entire industries and improve people’s lives. From the foundation of a start-up to its exit.
Founded in June 2019, with a focus on high-performance medical devices, the Innovation Center of High-Performance Medical Device is devoted to boosting collaboration as well as in-depth integration and innovation of the “Clinical Practice – Scientific Research – Industry – Market” ecosystem to build high-quality industrial clusters of medical devices by aggregating and utilizing the innovation resources of the Guangdong-Hong Kong-Macao Greater Bay Area and also international resources based on solid clinical practice and industrial basis of Guangdong Province.
LSP is one of Europe’s largest and most experienced healthcare investment firms. With a track record going back more than 30 years, we have built up an investment house that is dedicated to only one task: seeking, nurturing and growing healthcare investment opportunities with the potential to have a positive impact on society.
IPF Partners is a leading alternative financing provider focused on the healthcare sector. IPF Partners invests directly in emerging commercial stage pharma/biotech, medtech, diagnostics and IT healthcare companies. IPF Partners provides customised low- to non-dilutive debt and equity financing to market leading healthcare companies. The focus is on innovating products at commercial stage with a high potential in attractive markets. Typical deal size ranges from €5-20m+ over a 3- to 6-year duration.
We seek great entrepreneurs who wish to provide significant health benefits to people all over the world, making their lives better and easier. We are eager to tackle major problems in order to provide solutions to key medical and lifestyle challenges.
Sustainability is at the core of what we do. Our long-term success is built on an unwavering commitment to addressing global socio-economic and environmental challenges through the development of financial markets. Our culture puts clients first, delivers outstanding products and services, and upholds the highest professional standards.
Because of our business, we are players in the world of healthcare and as such are committed to making our contribution to sustainable development. We adhere to the ESG practices we have established.
Kurma Partners is a key European venture capital group specialized in healthcare, with €470 million under management, with two dedicated franchises : Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).
Korys is the investment company of the Colruyt family. Our team of 30 professionals invests in companies and entrepreneurs taking a patient, well-thought-out and sustainable approach.
JAFCO Asia’s focus is on high growth technology-related companies in their early to growth-stage. Sectors favored include mobile and internet technology, consumer & services related, cyber security, medical/healthcare and renewable energy. JAFCO Asia also has an impressive track record of successful IPO, M&A and trade sale investment exits.
We are approachable. We connect with you from the very first meeting. We are direct, and fast-moving, and get right to the point. We respect our founders. We make a point of working in a friendly culture. We do not like corporate bureaucracy. We understand from the word Go what you do and why it’s important. We love deeptech. Not just that it’s transformative – we really know the science that makes it work.
IPF Partners is a leading alternative financing provider focused on the healthcare sector. IPF Partners invests directly in emerging commercial stage pharma/biotech, medtech, diagnostics and IT healthcare companies. IPF Partners provides customised low- to non-dilutive debt and equity financing to market leading healthcare companies. The focus is on innovating products at commercial stage with a high potential in attractive markets. Typical deal size ranges from €5-20m+ over a 3- to 6-year duration.
The Hong Kong Economic and Trade Office in Berlin, in collaboration with InvestHK, a government body tasked to facilitate inward investment, provides assistance to corporations and individuals looking for direct investment opportunities in Hong Kong
i&i Prague scouts and supports the growth through discovery, pre-seed or seed phase of the most promising projects with innovative potential in the fields of MedTech, Diagnostics and Drug Discovery from the Central Europe region.
The Hong Kong Economic and Trade Office in Berlin, in collaboration with InvestHK, a government body tasked to facilitate inward investment, provides assistance to corporations and individuals looking for direct investment opportunities in Hong Kong
We are passionate about building technology companies with innovative business models that can transform industries. We have a broad industry focus – our experience and our partnerships help us to take a deep dive across different industries.
We are passionate about building technology companies with innovative business models that can transform industries. We have a broad industry focus – our experience and our partnerships help us to take a deep dive across different industries.
We are passionate about building technology companies with innovative business models that can transform industries. We have a broad industry focus – our experience and our partnerships help us to take a deep dive across different industries.
InHealth Ventures backs founders who are on a mission to solve painful, pervasive healthcare challenges. We want to invest in companies that can increase access to care, improve clinical outcomes and reduce the financial burden associated with treatment that too many families and health systems face. Through our link with InHealth, we have a breadth of commercial and operational experience that allows us to support portfolio companies across R&D, go-to-market, and regulatory strategy.
Induran is a Venture Philanthropy General Partnership that accelerates technologies that have impact on problems confronting humanity. We have developed products in biofuels, agricultural biotech, anti viral therapeutics, drug delivery and molecular diagnostics.
imec.xpand is an independently managed value-add venture capital fund that focuses on hardware-based nanotechnology innovations where imec technology, expertise, network and infrastructure will play a differentiating role.
1315 Capital provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty therapeutics companies, the latter including businesses focused on cost containment and digital health. We believe that these investment areas are attractive largely due to numerous […]
Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine.
1315 Capital provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty therapeutics companies, the latter including businesses focused on cost containment and digital health. We believe that these investment areas are attractive largely due to numerous […]
